Site search

Clear filter
2897 results for '' found
AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SAFETY DATA OF FACTOR IX OR FACTOR VIII PROPHYLAXIS REPLACEMENT THERAPY IN THE
AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SAFETY DATA OF FACTOR IX OR FACTOR VIII PROPHYLAXIS REPLACEMENT THERAPY IN THE
/
A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma. (ACTRN12620000490976)
A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma. (ACTRN12620000490976)
/
A randomised, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (NCT06097260)
/
Adding mitomycin C to BCG as adjuvant intravesical therapy for high risk, non–muscle invasive bladder cancer: A randomised phase 3 trial (ACTRN12613000513718)
Adding mitomycin C to BCG as adjuvant intravesical therapy for high risk, non–muscle invasive bladder cancer: A randomised phase 3 trial (ACTRN12613000513718)
/
Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Women with Schizophrenia: a double-blind, randomized, placebo controlled trial (NCT04113993)
Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Women with Schizophrenia: a double-blind, randomized, placebo controlled trial (NCT04113993)
/
Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Men with Schizophrenia: a double-blind, randomized, placebo-controlled trial (ACTRN12619001471178p)
Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Men with Schizophrenia: a double-blind, randomized, placebo-controlled trial (ACTRN12619001471178p)
/
A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATE
A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATE
/
Full thickness Burn Wound Closure Using Bioengineered Skin: A Feasibility Study (ACTRN12623000349640)
Full thickness Burn Wound Closure Using Bioengineered Skin: A Feasibility Study (ACTRN12623000349640)
/
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients with Relapsed or Re
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients with Relapsed or Re
/
A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer (NCT06092580)
A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer (NCT06092580)
/
61 62 63 64 65